Efficacy of plasma vascular endothelial growth factor in monitoring first-line chemotherapy in patients with advanced non-small cell lung cancer

Table 5 Diagnostic profiles of VEGF levels available before second and third cycles of chemotherapy for the prediction of cancer progression or response to therapy

	AUC	Cut-off	Sensitivity %	Specificity %	LR
	(95% CI)	VEGF (pg/mL)	(95% CI)	(95% CI)
Evaluation 1 (R + NC vs P)
VEGF BV2	0.805 (0.675-0.935)	312.6	71.4 (42.0-90.4)	71.4 (51.1-86.0)	2.5
VEGF BV3	0.895 (0.797-0.993)	355.4	85.7 (56.2-97.5)	89.3 (70.6-97.2)	8.0
Evaluation 2 (R vs NC + P)
VEGF BV2	0.724 (0.553-0.893)	232.1	76.9 (55.9-90.2)	75.0 (47.4-91.7)	3.1
VEGF BV3	0.817 (0.679-0.956)	261.0	76.9 (55.9-90.2)	75.0 (47.4-91.7)	3.1

BV2, and BV3, baseline VEGF levels before therapy cycle 2 to 3, respectively; AUC, area under receiver operating characteristic
(ROC) curve; 95% CI, 95% confidence interval; LR, likelihood ratio; R, remission; NC, no change; P, progression.

ISSN: 1471-2407